European Biomarkers Summit Agenda

Registration

Signaling Networks in Cancer Tissues: Protein Analysis of Formalin-Fixed Tissue Sections
Michael Pawlak, Head, University of Tuebingen, Germany

A high throughput analysis of FFPE tissue sections using Reverse-phase Protein Arrays was established that allows the generation of complex signalling profiles. Molecular profiles from more than 150 signaling proteins will be presented. Their use for defining pharmacodynamic and patient stratification biomarkers will be discussed.

Genome-Scale Quantitative Tumour Proteomics for Cancer Biomarkers Discovery
Metodi Metodiev, Biological Safety Officer, University of Essex, United Kingdom

Genome-scale quantitative tumour proteomics for cancer biomarkers discovery.

Coffee Break and Networking in the Exhibition Hall

Harmonization and Standardization of CNS Biomarkers
Rivka Ravid, Brain Bank Consultant, Royal Dutch Academy of Sciences, Netherlands

Cerebrospinal Fluid Biomarkers for Neurodegeneration
Niklas Mattsson, Medical Doctor & Researcher, Sahlgrens University Hospital, Sweden

Cerebrospinal fluid (CSF) biomarkers may be used for molecular diagnostics of several diseases, including Alzheimer's disease. They are used in clinical routine, research and drug development. To support the standardization of CSF biomarkers, a global external quality control program was recently initiated.

Lunch and Networking in the Exhibition Hall

Poster Session

Mode of Action Analysis and Biomarker Discovery Using Mass Spectrometry-Based Phosphoproteomics Technologies
Andreas Jenne, CEO, Kinaxo Biotechnologies, Germany

Global quantitative phosphoproteomics facilitates detailed mode-of-action analysis of targeted drugs and discovery of regulated protein phosphorylations that can function as response prediction biomarkers for patient stratification.

Quantitative Proteomics For Biomarker Discovery and Validation: Prostate Cancer Case Study
Stephen Pennington, Professor, University College Dublin, Ireland

There is an important need for clinically relevant biomarkers which will improve the diagnosis and the management of patients with prostate cancer. Here a strategy integrating label-free LC-MS based protein biomarker discovery with subsequent multiplexed validation by multiple reaction monitoring MS that is directed to the development of biomarkers of clinical utility for prostate cancer will be described.

Coffee Break and Networking in the Exhibition Hall

Networks as Markers – A New Concept That Has Entered Clinics.
Serhiy Souchelnytskyi, Associate Professor, Karolinska Institutet, Sweden

Reaction of a body to a treatment defines successfulness of the treatment. Dynamic Response Networks predicting such a reaction enter clinics. DRNets for management of breast cancer is an example of clinical applications.

Translating Lymphoma Gene Expression Signatures into Routine Clinical Biomarkers
Alison Banham, Reader, University of Oxford, United Kingdom

Gene expression profiling has identified clinically relevant subtypes of diffuse large B-cell lymphoma with distinct mechanisms of disease pathogenesis. Routine biomarkers are required to guide patient stratification for the next generation of molecular targeted therapies.

Close of Day One

Adaptive Learning and Simulation Approaches Enhance Molecular Diagnostics of Malignant and Infectious Diseases
Joachim Schultze, Director, University of Bonn, Germany

Novel approaches for the integration and use of transcriptome data to speed up the development process of molecular diagnostics in malignant and infectious diseases.

Coffee and Networking in the Exhibition Hall

Prostate Biomarkers in Translational Research – Are we on the Brink of Making a Difference?
Hayley Whitaker, Research Associate, Cancer Research UK, United Kingdom

Using a robust and rapid biomarker pipeline we are developing new biomarkers for prostate cancer diagnosis and prognosis to be used alone, or in combination with PSA.

Protein Profiling of Diseased Tissues Samples
Jan van Oostrum, Head of Business Development, Zeptosens - a Division of Bayer (Schweiz) AG, Switzerland

A systematic analysis of dynamic cellular networks provides an opportunity for the discovery of abnormalities in the signalling pathways of diseased tissue samples. We implemented a proteomics platform based on reverse arrays. Examples will be presented on how to stratify cancer tissues based on protein profiles

Lunch and Networking in the Exhibition Hall

Poster Session

Development of a Blood Based Molecular Test to Aid in the Diagnosis of Schizophrenia
Emanuel Schwarz, Post Doctoral Researcher, University of Cambridge, United Kingdom

We describe the validation of a serum-based test which can be used to help confirm the diagnosis of schizophrenia. Based on multiplexed immunoassays, a 51 analyte panel was developed and shown to be a sensitive and specific predictor of schizophrenia.

Translational Mechanistic Biomarkers of Drug-Induced Liver Injury
Dominic Williams, Senior Lecturer, , United Kingdom

The presentation details biomarkers of drug-induced liver injury from basic mechanisms in animal models through to the translation of two proteins, High Mobility Group Box-1 and Keratin-18 that are informative in the clinic.

Coffee and Networking in the Exhibition Hall

A New View on Biomarkers in Personalized and Systems Medicine for Metabolic Diseases
Ben van Ommen, , TNO, Netherlands

A change in prevention and therapy thus needs a very different biomarker approach, based on systems medicine and a resulting personalized targeted diagnosis / biomarker strategy. These concepts and application will be discussed.

Proximity Probing Assays For Sensitive Protein Biomarker Detection In Minute Sample Volumes Of Serum
Simon Fredriksson, CEO, Olink, Sweden

By converting putative biomarker proteins into ID-coded PCR amplicons, the proximity probing assays enable large scale studies of precious biobanked serum and plasma with fM sensitvity in 1 micro litre samples.

Close of Conference